Skip to main content

Advertisement

Log in

Mucosal Pigmentation Caused by Imatinib: Report of Three Cases

  • Case Report
  • Published:
Head and Neck Pathology Aims and scope Submit manuscript

Abstract

Imatinib mesylate (STI-571, Gleevec®), a tyrosine kinase inhibitor, is a first-line medication for treating chronic myeloid leukemia (CML). Clinical studies revealed very good hematological responses without significant side effects. However, imatinib may lead to mucosal pigmentation. Three patients, two males aged 64 and 53 and one female aged 29 presented with a painless, diffuse, grey-blue pigmentation of the mucosa of the hard palate. Both male patients had a history of CML and had been on imatinib for 4 and 10 years, respectively. The female patient had been on imatinib for 4 years for pelvic fibromatosis. Histopathologically, deposition of fine, dark-brown, spherical granules was noted within the connective tissue. There was no inflammation or hemorrhage, and no melanosis or melanocytic hyperplasia in the epithelium. The granules stained positively for both Fontana-Masson and Prussian blue stains. Imatinib-induced pigmentation is similar to that caused by other medications such as minocycline and anti-malarial medications, namely the deposition of a drug metabolite containing melanin and iron.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med. 2001;344(14):1031–7.

    Article  PubMed  CAS  Google Scholar 

  2. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med. 2002;346(9):645–52.

    Article  PubMed  CAS  Google Scholar 

  3. Savage DG, Antman KH. Imatinib mesylate—a new oral targeted therapy. New Engl J Med. 2002;346(9):683–93.

    Article  PubMed  CAS  Google Scholar 

  4. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004;15(2):358–9.

    Article  PubMed  CAS  Google Scholar 

  5. Resende RG, Teixeira RG, Vasconcelos FD, Silva ME, Abreu MH, Gomez RS. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Craniomaxillofac Surg. 2011. doi:10.1016/j.jcms.2011.07.010.

  6. Lewis DM. Diffuse pigmentation of the palate. J Okla Dent Assoc. 2009;100(8):24–5.

    PubMed  Google Scholar 

  7. Mattsson U, Halbritter S, Morner Serikoff E, Christerson L, Warfvinge G. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(5):e12–6.

    Article  PubMed  CAS  Google Scholar 

  8. McPherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009;23(1):82–3.

    Article  PubMed  CAS  Google Scholar 

  9. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995;32(2 Pt 1):241–7.

    Article  PubMed  CAS  Google Scholar 

  10. Granstein RD, Sober AJ. Drug- and heavy metal–induced hyperpigmentation. J Am Acad Dermatol. 1981;5(1):1–18.

    Article  PubMed  CAS  Google Scholar 

  11. Koranda FC. Antimalarials. J Am Acad Dermatol. 1981;4(6):650–5.

    Article  PubMed  CAS  Google Scholar 

  12. Kleinegger CL, Hammond HL, Finkelstein MW. Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(2):189–94.

    Article  PubMed  CAS  Google Scholar 

  13. Lerman MA, Karimbux N, Guze KA, Woo SB. Pigmentation of the hard palate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(1):8–12.

    Article  PubMed  Google Scholar 

  14. Perusse R, Morency R. Oral pigmentation induced by Premarin. Cutis. 1991;48(1):61–4.

    PubMed  CAS  Google Scholar 

  15. Solomon S. POMC-derived peptides and their biological action. Ann NY Acad Sci. 1999;885:22–40.

    Article  PubMed  CAS  Google Scholar 

  16. Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res. 2003;16(3):287–96.

    Article  PubMed  CAS  Google Scholar 

  17. Treister NS, Magalnick D, Woo SB. Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(6):718–25.

    Article  PubMed  Google Scholar 

  18. Kumar B, Saraswat A, Kaur I. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol. 2002;27(1):8–13.

    Article  PubMed  CAS  Google Scholar 

  19. Issaivanan M, Mitu PS, Manisha C, Praveen K. Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review. Pediatr Dermatol. 2004;21(2):124–7.

    Article  PubMed  CAS  Google Scholar 

  20. Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets. 2005;16(3–4):181–4.

    Article  PubMed  CAS  Google Scholar 

  21. Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol. 1992;31(7):458–66.

    Article  PubMed  Google Scholar 

  22. Kelsey PR. Multiple longitudinal pigmented nail bands during hydroxyurea therapy. Clin Lab Haematol. 1992;14(4):337–8.

    Article  PubMed  CAS  Google Scholar 

  23. Meleti M, Vescovi P, Mooi WJ, van der Waal I. Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(5):606–16.

    Article  PubMed  Google Scholar 

  24. De Schepper S, Boucneau J, Lambert J, Messiaen L, Naeyaert JM. Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res. 2005;18(1):13–24.

    Article  PubMed  Google Scholar 

  25. Kim IS, Kim ER, Nam HJ, Chin MO, Moon YH, Oh MR, et al. Activating mutation of GS alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. Hormone Res. 1999;52(5):235–40.

    Article  PubMed  CAS  Google Scholar 

  26. Lin-Marq N, Borel C, Antonarakis SE. Peutz-Jeghers LKB1 mutants fail to activate GSK-3beta, preventing it from inhibiting Wnt signaling. Mol Genet Genomics. 2005;273(2):184–96.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chia-Cheng Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, CC., Malik, S.M., Blaeser, B.F. et al. Mucosal Pigmentation Caused by Imatinib: Report of Three Cases. Head and Neck Pathol 6, 290–295 (2012). https://doi.org/10.1007/s12105-011-0325-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12105-011-0325-4

Keywords

Navigation